Cancer Advisor

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 15, 2026 Key takeaway: Cancer stem cells (CSCs) are not necessarily a tiny, fixed population representing “1% of a tumor.” Their frequency varies dramatically between cancer types and experimental definitions. Modern research increasingly views CSCs as a dynamic cellular state that cancer cells can enter and exit. This plasticity may be as important therapeutically as the CSC population itself. Abstract Cancer stem cells (CSCs) are cancer-cell populations or cellular states characterized by properties such as self-renewal, tumor initiation, differentiation capacity, metabolic adaptation and resistance to therapy. CSC biology has become increasingly important in research on cancer recurrence, metastasis and treatment resistance. However, the traditional model of CSCs as a rare, permanently defined population is being revised. Contemporary evidence supports a more dynamic mo...

Medically Reviewed by: OneDayMD Editorial Team | Written by:     Dr Frank Yap, MD | Last Updated:   August  8, 2026 Can ivermectin, mebendazole, fenbendazole or niclosamide overcome Tagrisso resistance? These repurposed drugs have generated interest because some affect signaling pathways involved in cancer-cell survival and drug resistance. However, the current evidence does not establish any of them as clinically proven treatments for osimertinib-resistant EGFR-mutated lung cancer. Tagrisso (osimertinib) is a third-generation EGFR tyrosine kinase inhibitor used extensively for EGFR-mutated non-small-cell lung cancer (NSCLC). Although osimertinib can produce prolonged disease control, acquired resistance eventually develops in most patients with advanced disease. Key takeaway: The scientifically strongest approach to Tagrisso resistance is not to empirically add several repurposed drugs. It is to identify the resistance mechanism through molecular profili...

Quick Answer: This framework merges OneDayMD's I-PREVENT Cancer Protocol with Dr. Paul Marik and Dr. Justus Hope's ROOT Protocol into a single five-layer system. Layer 1 is diet, metabolic health, and lifestyle — the original I-PREVENT foundation. Layers 2–3 are food-derived nutraceuticals (EGCG, curcumin, vitamin D3, omega-3, berberine, sulforaphane, vitamin C, magnesium, zinc, garlic, melatonin, and more), graded from strongest human-trial evidence to broader supporting data. Layer 4 is an optional Aged Garlic Extract upgrade. Layer 5 is Root 9 — the prescription drugs celecoxib, ivermectin, and mebendazole — which both authors scope strictly to people with confirmed hereditary cancer syndromes under specialist supervision, not general use. This is a prevention framework for healthy adults, not a cancer treatment protocol. Medically reviewed and updated by the OneDayMD Editorial Team | Merged framework published July 12, 2026 | Synthesizes and supersedes two ...